Pages that link to "Q43770759"

The following pages link to Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults (Q43770759):

Displaying 31 items.

• Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation (Q24186451) (← links)
• Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas (Q24200521) (← links)
• Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas (Q24234049) (← links)
• Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial (Q33375139) (← links)
• Comparison of two methods for carboplatin dosing in children with retinoblastoma (Q34065022) (← links)
• EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model (Q34206278) (← links)
• Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial (Q34446661) (← links)
• New approaches to hematopoietic cell transplantation in oncology (Q35064139) (← links)
• Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy (Q35102499) (← links)
• All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage (Q35884399) (← links)
• Toxicity of the topoisomerase I inhibitors (Q36040744) (← links)
• Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission (Q36212437) (← links)
• Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma (Q36499230) (← links)
• A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up (Q36970948) (← links)
• Management and outcome of stage 3 neuroblastoma (Q37056086) (← links)
• The role of 131I-MIBG in high-risk neuroblastoma treatment (Q37591069) (← links)
• Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. (Q38608663) (← links)
• Desmoplastic Small Round Cell Tumor: Pathology, Genetics, and Potential Therapeutic Strategies. (Q38952891) (← links)
• Desmoplastic small round cell tumor 20 years after its discovery (Q39025917) (← links)
• A pilot trial of tandem autologous peripheral blood progenitor cell transplantation following high-dose thiotepa and carboplatin in children with poor-risk central nervous system tumors (Q40518066) (← links)
• KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. (Q41985731) (← links)
• Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma (Q43011641) (← links)
• A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia (Q44598660) (← links)
• Escalating topotecan in combination with treosulfan has acceptable toxicity in advanced pediatric sarcomas. (Q45911250) (← links)
• Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study (Q46165693) (← links)
• Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system (Q46884985) (← links)
• Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). (Q48372855) (← links)
• Topotecan for pediatric patients with resistant and recurrent solid tumors (Q50353862) (← links)
• Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma (Q50464042) (← links)
• Misinterpretation of a Calvert-Derived Formula Leading to Carboplatin Overdose in Two Children (Q79121503) (← links)
• Topoisomerase I interactive agents (Q80510499) (← links)